283 related articles for article (PubMed ID: 30268764)
1. Characteristics and Outcomes of BI-RADS 3 Lesions on Breast MRI.
Panigrahi B; Harvey SC; Mullen LA; Falomo E; Di Carlo P; Lee B; Myers KS
Clin Breast Cancer; 2019 Feb; 19(1):e152-e159. PubMed ID: 30268764
[TBL] [Abstract][Full Text] [Related]
2. Characteristics, Malignancy Rate, and Follow-up of BI-RADS Category 3 Lesions Identified at Breast MR Imaging: Implications for MR Image Interpretation and Management.
Chikarmane SA; Birdwell RL; Poole PS; Sippo DA; Giess CS
Radiology; 2016 Sep; 280(3):707-15. PubMed ID: 27089027
[TBL] [Abstract][Full Text] [Related]
3. Frequency of Malignancy and Imaging Characteristics of Probably Benign Lesions Seen at Breast MRI.
Grimm LJ; Anderson AL; Baker JA; Johnson KS; Walsh R; Yoon SC; Ghate SV
AJR Am J Roentgenol; 2015 Aug; 205(2):442-7. PubMed ID: 26204298
[TBL] [Abstract][Full Text] [Related]
4. Management for BI-RADS category 3 lesions detected in preoperative breast MR imaging of breast cancer patients.
Gweon HM; Cho N; Kim SY; Koo HR; Seo M; Chu A; Son EJ
Eur Radiol; 2017 Aug; 27(8):3211-3216. PubMed ID: 28083693
[TBL] [Abstract][Full Text] [Related]
5. BI-RADS lesion characteristics predict likelihood of malignancy in breast MRI for masses but not for nonmasslike enhancement.
Gutierrez RL; DeMartini WB; Eby PR; Kurland BF; Peacock S; Lehman CD
AJR Am J Roentgenol; 2009 Oct; 193(4):994-1000. PubMed ID: 19770321
[TBL] [Abstract][Full Text] [Related]
6. Frequency and Cancer Yield of BI-RADS Category 3 Lesions Detected at High-Risk Screening Breast MRI.
Edmonds CE; Lamb LR; Mercaldo SF; Sippo DA; Burk KS; Lehman CD
AJR Am J Roentgenol; 2020 Feb; 214(2):240-248. PubMed ID: 31799867
[No Abstract] [Full Text] [Related]
7. BI-RADS® 3 lesions at contrast-enhanced breast MRI: is an initial short-interval follow-up necessary?
Bahrs SD; Baur A; Hattermann V; Hahn M; Vogel U; Claussen CD; Siegmann-Luz KC
Acta Radiol; 2014 Apr; 55(3):260-5. PubMed ID: 23969262
[TBL] [Abstract][Full Text] [Related]
8. BI-RADS category 3, 4, and 5 lesions identified at preoperative breast MRI in patients with breast cancer: implications for management.
Lee SE; Lee JH; Han K; Kim EK; Kim MJ; Moon HJ; Yoon JH; Park VY
Eur Radiol; 2020 May; 30(5):2773-2781. PubMed ID: 32006168
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of probably benign breast MRI lesions.
Eby PR; DeMartini WB; Gutierrez RL; Saini MH; Peacock S; Lehman CD
AJR Am J Roentgenol; 2009 Sep; 193(3):861-7. PubMed ID: 19696303
[TBL] [Abstract][Full Text] [Related]
10. Is a one-year follow-up an efficient method for better management of MRI BI-RADS(®) 3 lesions?
Boisserie-Lacroix M; Ziadé C; Hurtevent-Labrot G; Ferron S; Brouste V; Lippa N
Breast; 2016 Jun; 27():1-7. PubMed ID: 27212693
[TBL] [Abstract][Full Text] [Related]
11. Magnetic resonance imaging of the breast as a problem-solving method: to be or not to be?
Oztekin PS; Kosar PN
Breast J; 2014; 20(6):622-31. PubMed ID: 25200378
[TBL] [Abstract][Full Text] [Related]
12. Breast lesions classified as probably benign (BI-RADS 3) on magnetic resonance imaging: a systematic review and meta-analysis.
Spick C; Bickel H; Polanec SH; Baltzer PA
Eur Radiol; 2018 May; 28(5):1919-1928. PubMed ID: 29168006
[TBL] [Abstract][Full Text] [Related]
13. [Diagnostic value of a breast MRI score for the prediction of malignancy of breast lesions detected solely with MRI].
Siegmann KC; Moron HU; Baur A; Hahn M; Vogel U; Claussen CD; Bitzer M
Rofo; 2009 Jun; 181(6):556-63. PubMed ID: 19452398
[TBL] [Abstract][Full Text] [Related]
14. Benign (BI-RADS 2) lesions in breast MRI.
Spick C; Szolar DH; Tillich M; Reittner P; Preidler KW; Baltzer PA
Clin Radiol; 2015 Apr; 70(4):395-9. PubMed ID: 25649442
[TBL] [Abstract][Full Text] [Related]
15. Breast imaging reporting and data system (BI-RADS) lexicon for breast MRI: interobserver variability in the description and assignment of BI-RADS category.
El Khoury M; Lalonde L; David J; Labelle M; Mesurolle B; Trop I
Eur J Radiol; 2015 Jan; 84(1):71-76. PubMed ID: 25454100
[TBL] [Abstract][Full Text] [Related]
16. Can Follow-up be Avoided for Probably Benign US Masses with No Enhancement on MRI?
Avendano D; Marino MA; Onishi N; Leithner D; Martinez DF; Gibbs P; Jochelson M; Pinker K; Morris EA; Sutton EJ
Eur Radiol; 2021 Feb; 31(2):975-982. PubMed ID: 32870394
[TBL] [Abstract][Full Text] [Related]
17. The Value of Lesion Size as an Adjunct to the BI-RADS-MRI 2013 Descriptors in the Diagnosis of Solitary Breast Masses.
Kawai M; Kataoka M; Kanao S; Iima M; Onishi N; Ohashi A; Sakaguchi R; Toi M; Togashi K
Magn Reson Med Sci; 2018 Jul; 17(3):203-210. PubMed ID: 29213007
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and Predictive Value of BI-RADS 3, 4, and 5 Lesions Detected on Breast MRI: Correlation with Study Indication.
Chikarmane SA; Tai R; Meyer JE; Giess CS
Acad Radiol; 2017 Apr; 24(4):435-441. PubMed ID: 27955878
[TBL] [Abstract][Full Text] [Related]
19. Background parenchymal enhancement on baseline screening breast MRI: impact on biopsy rate and short-interval follow-up.
Hambly NM; Liberman L; Dershaw DD; Brennan S; Morris EA
AJR Am J Roentgenol; 2011 Jan; 196(1):218-24. PubMed ID: 21178070
[TBL] [Abstract][Full Text] [Related]
20. ShearWave™ Elastography BE1 multinational breast study: additional SWE™ features support potential to downgrade BI-RADS®-3 lesions.
Schäfer FK; Hooley RJ; Ohlinger R; Hahne U; Madjar H; Svensson WE; Balu-Maestro C; Juhan V; Athanasiou A; Mundinger A; Order B; Locatelli M; Cosgrove D; Wolf OJ; Henry JP; Moutfi M; Gay JM; Cohen-Bacrie C
Ultraschall Med; 2013 Jun; 34(3):254-9. PubMed ID: 23709241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
